In Rare Cannabinoids, BioMedican Sees Alphabet Of Potential Dietary And Drug Ingredients
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.
You may also be interested in...
Groups of House and Senate members who opposed legislation to de-schedule hemp as a controlled substance in 2018 remain opposed to also legalizing cannabis and could stifle support for making lawful hemp’s use in supplements.
BioMedican needs support until it can begin generating revenues and conduct an IPO. Businesses already marketing cannabinoid supplements receive more funding, or in some cases are acquired, as well as expand distribution.
FDA To Consider Regulatory Shift Making Cannabis Ingredients Officially Eligible For Use In Dietary Supplements
FDA's prohibition against using ingredients derived from the cannabis plant in supplements and food isn't lifted by the farm bill President Trump signed on Dec. 20, but the agency recognizes sales of supplement and food products containing cannabidiol and other cannabis derivatives are exploding in the US.